Stocksigma LogoStocksigma Logo

Neuland Laboratories Accelerates Commercial Peptide Capacity Expansion Following Strong Revenue Growth

Neuland Laboratories operationalized the first of four commercial peptide modules on 15th Sep'26, investing $30 million to add 7,000 L total reactor

Neuland Laboratories Accelerates Commercial Peptide Capacity Expansion Following Strong Revenue Growth

Neuland Laboratories Ltd 路 Press Release 路 15 Sept 2026, 3:57 pm

Neuland Laboratories Accelerates Commercial Peptide Capacity Expansion Following Strong Revenue Growth Neuland Laboratories operationalized the first of four commercial peptide modules on 15th Sep'26, investing $30 million to add 7,000 L total reactor capacity (750 L SPPS, 6,250 L LPPS). Work on module two is advancing ahead of schedule, targeting up to 18,000 L capacity to capture expanding demand across obesity, metabolic, and oncology pipelines. Supported by 212 peptide specialists, this expansion follows a 116% YoY surge in Neuland鈥檚 latest quarterly revenues, driven by rising commercial contracts and clinical-stage projects.

Original exchange filing (PDF)

More announcements from Neuland Laboratories Ltd

All Neuland Laboratories Ltd announcements